Notably, while the TCF4-sensitive gene Cxcl10 has been proposed as a NASH biomarker29, the Lgals3 (also known as Galectin 3) inhibitor Belapectin is a promising medication for NASH currently under investigation and development for phase 3 clinical trials3,30. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatohepatitis.